Lermed leverages two fully human platforms. On one hand, our blood-based liquid biopsy technology is tailored to identify relevant biomarkers for drug efficacy and safety as well as patient stratification. On a second hand, our preclinical stem cell-based technology allows assessing drug candidate efficiency on patient-derived models. We are building a fully integrated workflow to conduct clinical trials in a dish to leverage the most of preclinical data and ensure the highest success rate during large scale clinical trials.

Interested in learning more or collaborating with us?